Horm Metab Res 2004; 36(10): 674-678
DOI: 10.1055/s-2004-826013
Original Basic
© Georg Thieme Verlag KG Stuttgart · New York

Testosterone Increases Osteoprotegerin mRNA Expression in Mouse Osteoblast Cells

Q.  Chen1 , H.  Kaji1 , M.  Kanatani1 , T.  Sugimoto1 , K.  Chihara1
  • 1Division of Endocrinology/Metabolism, Neurology and Hematology/Oncology, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine
Further Information

Publication History

Received 1 December 2003

Accepted after revision 25 March 2004

Publication Date:
03 November 2004 (online)

Abstract

The role that androgens play in the regulation of bone metabolism has been substantiated in animals and humans. We previously demonstrated that testosterone inhibits osteoclast differentiation stimulated by parathyroid hormone through the androgen receptor in mouse bone-cell cultures. However, the details of this mechanism are still unknown. The present study was aimed at examining whether testosterone would affect the mRNA levels of osteoprotegerin (OPG) and receptor activator of NfκB ligand (RANKL) in mouse bone-cell cultures as well as mouse osteoblastic cell-line, MC3T3-E1 cells by employing semi-quantitative RT-PCR. Testosterone increased OPG mRNA expression in both mouse bone-cell cultures and MC3T3-E1 cells. 10-8 M PTH-(1-34) as well as 10-8M 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] inhibited OPG mRNA expression in mouse bone cells. 10-8 M testosterone antagonized OPG mRNA expression inhibited by 10-8 M PTH-(1-34), but failed to affect OPG mRNA expression inhibited by 10-8 M 1,25(OH)2D3. 10-8 M α-dehydrotestosterone, a non-aromatizable androgen, increased OPG mRNA expression. On the other hand, testosterone did not affect RANKL mRNA expression in MC3T3-E1 or mouse bone cells. In conclusion, the present study demonstrated that testosterone increased OPG mRNA expression in mouse bone-cell cultures and the osteoblastic cell line. These effects are likely to take place through the androgen receptor.

References

  • 1 Orwoll E S, Klein R F. Osteoporosis in men.  Endocr Rev. 1995;  16 87-116
  • 2 Seeman E, Melton L J , O’Fallon W M, Riggs B L. Risk factors for spinal osteoporosis in men.  Am J Med. 1983;  75 977-983
  • 3 Francis R M. The effects of testosterone on osteoporosis in men.  Clin Endocrinol (Oxf). 1999;  50 411-414
  • 4 Vanderschueren D, Vandenput L, Boonsen S, van Herck E, Swinnen J V, Bouillon R. An aged rat model of partial androgen deficiency: prevention of both loss of bone and lean body mass by low-dose androgen replacement.  Endocrinology. 2000;  141 1642-1647
  • 5 Tobias J H, Gallagher A, Chambers T J. 5-alpha-Dihydrotestosterone partially restores cancellous bone volume in osteopenic ovariectomized rats.  Am J Physiol. 1994;  267 E853-859
  • 6 Mizuno Y, Hosoi T, Inoue S, Ikegami A, Kaneki M, Akedo Y, Nakamura T, Ouchi Y, Chan C, Orimo H. Immunocytochemical identification of androgen receptor in mouse osteoclast-like multinucleated cells.  Calcif Tissue Int. 1994;  54 325-329
  • 7 Pederson L, Kremer M, Judd J, Pascoe D, Spelsberg T C, Riggs B L, Oursler M J. Androgen regulates bone resorption activity of isolated osteoclasts in vitro. Proc. Natl Acad. Sci.  USA. 1999;  96 505-510
  • 8 Kaji H, Sugimoto T, Kanatani M, Nasu M, Chihara K. Estrogen blocks parathyroid hormone (PTH)-stimulated osteoclast-like cell formation by selectively affecting PTH-responsive cyclic adenosine monophosphate pathway.  Endocrinology. 1996;  137 2217-2224
  • 9 Chen Q, Kaji H, Sugimoto T, Chihara K. Testosterone inhibits osteoclast formation stimulated by parathyroid hormone through androgen receptor.  FEBS Letter. 2001;  491 91-93
  • 10 Simonet W S, Lacey D L, Dunstan C R, Kelley M, Chang M S, Luthy R, Nguyen H Q, Wooden S, Bennet L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan H L, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes T M, Hill D, Pattison W, Campbell P, Boyle W J. Osteoprotegrin: a novel secreted protein involved in the regulation of bone density.  Cell. 1997;  89 309-319
  • 11 Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashino K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegrin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.  Proc Natl Acad Sci USA. 1998;  95 3597-3602
  • 12 Suda T, Nakamura I, Jimi E, Takahashi N. Regulation of osteoclast function.  J Bone Miner Res. 1997;  12 869-879
  • 13 Saika M, Inoue D, Kido S, Matsumoto T. 17 beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha.  Endocrinology. 2001;  142 2205-2212
  • 14 Hofbauer L C, Khosla S, Dunstan C R, Lacey D L, Spelsberg T C, Riggs B L. Estrogen stimulates gene expression and protein production of osteoprotegrin in human osteoblastic cells.  Endocrinology. 1999;  140 4367-4370
  • 15 Kaji H, Sugimoto T, Kanatani M, Miyauchi A, Kimura T, Sakakibara S, Fukase M, Chihara K. Carboxyl-terminal parathyroid hormone fragments stimulates osteoclast-like cell formation and osteoclastic activity.  Endocrinology. 1994;  134 1897-1904
  • 16 Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.  Anal Biochem. 1987;  162 156-159
  • 17 Hornood N J, Elliott J, Martin T J, Gillespie M T. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegrin in osteoblastic stromal cells.  Endocrinology. 1998;  139 4743-4746
  • 18 Colvard D S, Eriksen E F, Keeting P E, Wilson E M, Lubahn D B, French F S, Riggs B L, Spelsberg T C. Identification of androgen receptors in normal human osteoblast-like cells.  Pro Natl Acad Sci USA. 1989;  86 854-857
  • 19 Schweikert H U, Rulf W, Niederle N, Schafer H E, Keck E, Kruck F. Testosterone metabolism in human bone.  Acta Endocrinol (Copenh). 1980;  95 258-264
  • 20 Huber D M, Bendixen A C, Pathrose P, Strivastava S, Dienger K M, Shevde N K, Pike J W. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor.  Endocrinology. 2001;  142 3800-3808
  • 21 Bellido T, Jilka R L, Boyce B F, Girasole G, Broxmeyer H, Dalrymple S A, Murray R, Manolagas S C. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor.  J Clin Invest. 1995;  95 2886-2895
  • 22 Hofbauer L C, Hicok K C, Khosla S. Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line.  J Cell Biochem. 1998;  71 96-108
  • 23 Kasperk C, Fitzsimmons R, Strong D, Mohan S, Jennings J, Wergedal J, Baylink D. Studies of the mechanism by which androgens enhance mitogenesis and differentiation in bone cells.  J Clin Endocrinol Metab. 1990;  71 1322-1329
  • 24 Anderson F H, Francis R M, Hindmarsh P, Fall C, Cooper C. Osteoporosis ’96 (Papapoulous SE, Lips P, Pols HAP, Johnston CC, Delmas PD, Eds). Amsterdam; Elsevier 1996: 377-381
  • 25 Slemenda C, Longcope C, Zhou L, Hui S L, Peacock M, Johnston C C. Sex steroids and bone mass in older man. Positive associations with serum estrogens and negative associations with androgens.  J Clin Invwst. 1997;  100 1755-1759
  • 26 Anderson F H, Francis R M, Selby P L, Cooper C. Sex hormones and osteoporosis in men.  Clacif Tissue Int. 1998;  62 185-188
  • 27 Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach K S, Simpson E R. Effects of testosterone and estradiol in a man with aromatase deficiency.  N Engl J Med. 1997;  337 91-95
  • 28 Smith E P, Boyd J, Frank G R, Takahashi H, Cohen R M, Specker B, Williams T C, Lubahn D B, Korach K S. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man.  N Engl J Med. 1994;  331 1056-1061
  • 29 Hofbauer L C, Khosla S. Androgen effects on bone metabolism: recent progress and controversies.  Eur J Endocrinol. 1999;  140 271-286
  • 30 Vanderschueren D, Boonen S, Bouillon R. Action of androgen versus estrogens in male skeletal homeostasis.  Bone. 1998;  23 391-394
  • 31 Vandenput L, Ederveen A G, Erben R G, Stahr K, Swinnen J V, van Herck E, Verstuyf A, Boonen S, Bouillon R, Vanderschueren D. Testosterone prevents orchidectomy-induced bone loss in estrogen receptor-alpha knockout mice.  Biochem Biophys Res Commun. 2001;  285 70-76
  • 32 Kawano H, Sato T, Yamada T, Matsumoto T, Sekine K, Watanabe T, Nakamura T, Fukuda T, Yoshimura K, Yoshizawa T, Fukuda T, Yoshimura K, Yoshizawa T, Aihara K, Yamamoto Y, Nakamichi Y, Metzger D, Chambon P, Nakamura K, Kawaguchi H, Kato S. Suppressive function of androgen receptor in bone resorption.  Pro Natl Acad Sci USA. 2003;  100 9416-9421
  • 33 Hofbauer L C, Hicok K C, Chen D, Khosla S. Regulation of osteoprotegrin production by androgens and anti-androgens in human osteoblastic lineage cells.  Eur J Endocrinol. 2002;  147 269-273

Toshitsugu Sugimoto, M.D.

Division of Endocrinology/Metabolism · Neurology and Hematology/Oncology · Department of Clinical Molecular Medicine · Kobe University Graduate School of Medicine

7-5-2 Kusunoki-cho · Chuo-ku · Kobe 650-0017 · Japan

Phone: +81(78)38258 85

Fax: +81(78)3825899

    >